European Antimicrobial Resistance Surveillance System

Early bactericidal activity

European Centre for Disease Prevention and Control

Epidemiological cut-off values

At the bacterial level, the ecological aspects refer to the competition between non-resistant strains and resistant strains of infectious bacteria. In untreated patients, non-resistant bacteria have a competitive advantage over the resistant strains that keeps the numbers of resistant bacteria extremely low. During treatment, however, the antibiotics kill off the normal bacteria and that allows the resistant strain to take over. As a result, a patient on antibiotics becomes a potential source of infection with resistant bacteria. This continues as long as the treatment lasts. After the treatment is ended, the population of non-resistant bacteria of all types rebounds and the population of resistant bacteria begins to drop until the patient ceases acting as a source. The clinical significance of this is that antibiotics that may benefit the individual (actual) patient may create a serious and detrimental problem to the general patient community.

European Economic Area

European Food Safety Authority

Electronic Health Records/Electr. Medical Records/Electr. Patient Records; PCHR’s refer to so-called patient- or personally controlled health records

European Medicines Agency

European Medicines Agency

European Gram Negative AntiBacteriaL Engine: www.nd4bb-enable.eu

End of treatment

European Surveillance of Antimicrobial Consumption Network

Extended-spectrum beta-lactamases (enzyme produced by ‘superbug’ bacteria making them resistant to common antibiotics such as penicillins and cephalosporins)

Extended spectrum cephalosporin

European Society for Clinical Microbiology and Infectious Diseases

European Sales and Use of Antimicrobials for Veterinary Medicine

European Surveillance of Veterinary Antimicrobial Consumption

European Union

European Committee on Antimicrobial Susceptibility Testing